The Quantellect read.As of Nov 19, 2026, 12 active firms cover Evommune, Inc: 9 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $8.00 to $53.00 (about 6.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $33.00 sits 378% above the current $6.90. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.87 next quarter toward $-3.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy18%
Buy867%
Neutral325%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$33.00
+378.3% upside
Average target across 10 active firms as of Nov 19, 2026 vs $6.90 current
Highest Target$53.00
Average Target$33.00
Lowest Target$8.00
Detailed analyst forecasts for EVMN
Showing 1–12 of 12 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 9 of 12 active firms rate EVMN a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
EVMN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.87
Range $-1.01 – $-0.67 · 4 analysts
Next period, 4 analysts expect Evommune, Inc. to earn $-0.87 a share (range $-1.01 – $-0.67), versus — a year earlier. Full-year consensus is $-3.27, growing to $-3.48 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $555.6K, rising to $777.8K next year.
Top analysts covering Evommune, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EVMN.
#1
Serge Belanger
Needham · Rank #129
Buy
$28.00+305.8% to target
Overall win rate
46%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Neutral
No targeton EVMN
Overall win rate
33%
+ Follow
#3
Andreas Argyrides
Oppenheimer · Rank #380
Buy
$42.00+508.7% to target
Overall win rate
41%
+ Follow
#4
Thomas Smith
Leerink Partners · Rank #412
Buy
$22.00+218.8% to target
Overall win rate
41%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #502
Buy
$21.00+204.3% to target
Overall win rate
26%
+ Follow
EVMN stock forecast FAQ
What is EVMN's average 12-month price target?+
The 10 active firms with a live target average $33.00 for Evommune, Inc. over the next 12 months, ranging from a $53.00 high to a $8.00 low, as of Nov 19, 2026.
Is EVMN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for EVMN?+
The Street-high target is $53.00 (Clear Street), and the Street-low is $8.00 (UBS). The average of all 10 active-firm targets is $33.00.
How many active Wall Street firms cover EVMN?+
12 active firms have a recognized rating on Evommune, Inc. as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering EVMN?+
Among analysts who currently cover EVMN, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #129). Their current call is Buy with a $28.00 target.
What is Evommune, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.87 per share (range $-1.01 – $-0.67) across 4 analysts. Full-year EPS is projected at $-3.27, rising to $-3.48 the following year.
How much revenue is Evommune, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $555.6K, growing to $777.8K next year.
Have analysts been upgrading or downgrading EVMN lately?+
As of Nov 19, 2026, 9 of 12 active firms rate EVMN a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EVMN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.